BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 25980013)

  • 1. Platelet-activating factor receptor contributes to antileishmanial function of miltefosine.
    Gangalum PR; de Castro W; Vieira LQ; Dey R; Rivas L; Singh S; Majumdar S; Saha B
    J Immunol; 2015 Jun; 194(12):5961-7. PubMed ID: 25980013
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Miltefosine promotes IFN-gamma-dominated anti-leishmanial immune response.
    Wadhone P; Maiti M; Agarwal R; Kamat V; Martin S; Saha B
    J Immunol; 2009 Jun; 182(11):7146-54. PubMed ID: 19454711
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of Leishmania donovani-infected hamsters with miltefosine: analysis of cytokine mRNA expression by real-time PCR, lymphoproliferation, nitrite production and antibody responses.
    Gupta R; Kushawaha PK; Samant M; Jaiswal AK; Baharia RK; Dube A
    J Antimicrob Chemother; 2012 Feb; 67(2):440-3. PubMed ID: 22121191
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Visceral leishmanicidal activity of hexadecylphosphocholine (miltefosine) in mice deficient in T cells and activated macrophage microbicidal mechanisms.
    Murray HW; Delph-Etienne S
    J Infect Dis; 2000 Feb; 181(2):795-9. PubMed ID: 10669380
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CpG oligodeoxynucleotide augments the antileishmanial activity of miltefosine against experimental visceral leishmaniasis.
    Sane SA; Shakya N; Haq W; Gupta S
    J Antimicrob Chemother; 2010 Jul; 65(7):1448-54. PubMed ID: 20495208
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination of paromomycin and miltefosine promotes TLR4-dependent induction of antileishmanial immune response in vitro.
    Das S; Rani M; Pandey K; Sahoo GC; Rabidas VN; Singh D; Das P
    J Antimicrob Chemother; 2012 Oct; 67(10):2373-8. PubMed ID: 22761329
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improved treatment of visceral leishmaniasis (kala-azar) by using combination of ketoconazole, miltefosine with an immunomodulator-Picroliv.
    Shakya N; Sane SA; Vishwakarma P; Bajpai P; Gupta S
    Acta Trop; 2011 Aug; 119(2-3):188-93. PubMed ID: 21679679
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inactivation of the miltefosine transporter, LdMT, causes miltefosine resistance that is conferred to the amastigote stage of Leishmania donovani and persists in vivo.
    Seifert K; Pérez-Victoria FJ; Stettler M; Sánchez-Cañete MP; Castanys S; Gamarro F; Croft SL
    Int J Antimicrob Agents; 2007 Sep; 30(3):229-35. PubMed ID: 17628445
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nanotized Curcumin and Miltefosine, a Potential Combination for Treatment of Experimental Visceral Leishmaniasis.
    Tiwari B; Pahuja R; Kumar P; Rath SK; Gupta KC; Goyal N
    Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 28031196
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Miltefosine--discovery of the antileishmanial activity of phospholipid derivatives.
    Croft SL; Engel J
    Trans R Soc Trop Med Hyg; 2006 Dec; 100 Suppl 1():S4-8. PubMed ID: 16904717
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Leptin augments protective immune responses in murine macrophages and enhances potential of miltefosine against experimental visceral leishmaniasis.
    Shivahare R; Ali W; Vishwakarma P; Natu SM; Puri SK; Gupta S
    Acta Trop; 2015 Oct; 150():35-41. PubMed ID: 26119043
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lipase Precursor-Like Protein Promotes Miltefosine Tolerance in Leishmania donovani by Enhancing Parasite Infectivity and Eliciting Anti-inflammatory Responses in Host Macrophages.
    Deep DK; Singh R; Kulshrestha A; Wajid S; Salotra P
    Antimicrob Agents Chemother; 2018 Dec; 62(12):. PubMed ID: 30297367
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Miltefosine resistance in Leishmania donovani involves suppression of oxidative stress-induced programmed cell death.
    Mishra J; Singh S
    Exp Parasitol; 2013 Oct; 135(2):397-406. PubMed ID: 23968687
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Augmentation of antileishmanial efficacy of miltefosine in combination with tuftsin against experimental visceral leishmaniasis.
    Shakya N; Sane SA; Haq W; Gupta S
    Parasitol Res; 2012 Aug; 111(2):563-70. PubMed ID: 22392136
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Miltefosine triggers a strong proinflammatory cytokine response during visceral leishmaniasis: role of TLR4 and TLR9.
    Mukherjee AK; Gupta G; Adhikari A; Majumder S; Kar Mahapatra S; Bhattacharyya Majumdar S; Majumdar S
    Int Immunopharmacol; 2012 Apr; 12(4):565-72. PubMed ID: 22361489
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Leishmania donovani: CD2 biased immune response skews the SAG mediated therapy for a predominant Th1 response in experimental infection.
    Bimal S; Sinha S; Singh SK; Narayan S; Kumar V; Verma N; Ranjan A; Sinha PK; Das VN; Pandey K; Kar SK; Das P
    Exp Parasitol; 2012 Jul; 131(3):274-82. PubMed ID: 22580024
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activities of hexadecylphosphocholine (miltefosine), AmBisome, and sodium stibogluconate (Pentostam) against Leishmania donovani in immunodeficient scid mice.
    Escobar P; Yardley V; Croft SL
    Antimicrob Agents Chemother; 2001 Jun; 45(6):1872-5. PubMed ID: 11353640
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Possible mechanism of miltefosine-mediated death of Leishmania donovani.
    Verma NK; Dey CS
    Antimicrob Agents Chemother; 2004 Aug; 48(8):3010-5. PubMed ID: 15273114
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro activity of new N-benzyl-1H-benzimidazol-2-amine derivatives against cutaneous, mucocutaneous and visceral Leishmania species.
    Nieto-Meneses R; Castillo R; Hernández-Campos A; Maldonado-Rangel A; Matius-Ruiz JB; Trejo-Soto PJ; Nogueda-Torres B; Dea-Ayuela MA; Bolás-Fernández F; Méndez-Cuesta C; Yépez-Mulia L
    Exp Parasitol; 2018 Jan; 184():82-89. PubMed ID: 29191699
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ex vivo host and parasite response to antileishmanial drugs and immunomodulators.
    Gonzalez-Fajardo L; Fernández OL; McMahon-Pratt D; Saravia NG
    PLoS Negl Trop Dis; 2015 May; 9(5):e0003820. PubMed ID: 26024228
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.